Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (211-220 of 353) with videos related to

Pageof 36
Sort By:
European Heart Journal|April 13, 2006
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trialPadma Kaul, Wei-Ching Chang, A Michael Lincoff, et al.
American Heart Journal|April 29, 2006
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trialMatthews Chacko, A Michael Lincoff, Katherine E Wolski, et al.
Journal of Cardiology|December 2, 2017
Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysisXiaofang Zeng, A Michael Lincoff, Stefanie Schulz-Schüpke, et al.
Circulation. Cardiovascular Quality and Outcomes|September 23, 2025
Temporal Trends, Patient Characteristics, and Outcomes of Type 2 Versus Type 1 Myocardial Infarction Among Medicare BeneficiariesAmgad Mentias, Neil Keshvani, Milind Y Desai, et al.
American Heart Journal|April 17, 2025
Association of testosterone-induced increase in neutrophil and monocyte counts with thromboembolic events: The TRAVERSE trialThiago Gagliano-Jucá, Karol M Pencina, Yili V Shang, et al.
JAMA Cardiology|December 23, 2025
Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical TrialStephen J Nicholls, Donna H Ryan, John Deanfield, et al.
American Heart Journal|September 11, 2013
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trialA Michael Lincoff, Jean-Claude Tardif, Bruce Neal, et al.
Journal of the American College of Cardiology|June 21, 2005
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trialHitinder S Gurm, Ian J Sarembock, Dean J Kereiakes, et al.
The American Journal of Cardiology|December 28, 2014
Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarctionJosephine Warren, Roxana Mehran, Jennifer Yu, et al.
Circulation|April 30, 2003
Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injuryZhongmin Zhou, Kai Wang, Marc S Penn, et al.
Pageof 36

Showing results (211-220 of 353) with videos related to

Sort By:
Pageof 36
European Heart Journal|April 13, 2006
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trialPadma Kaul, Wei-Ching Chang, A Michael Lincoff, et al.
American Heart Journal|April 29, 2006
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trialMatthews Chacko, A Michael Lincoff, Katherine E Wolski, et al.
Journal of Cardiology|December 2, 2017
Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysisXiaofang Zeng, A Michael Lincoff, Stefanie Schulz-Schüpke, et al.
Circulation. Cardiovascular Quality and Outcomes|September 23, 2025
Temporal Trends, Patient Characteristics, and Outcomes of Type 2 Versus Type 1 Myocardial Infarction Among Medicare BeneficiariesAmgad Mentias, Neil Keshvani, Milind Y Desai, et al.
American Heart Journal|April 17, 2025
Association of testosterone-induced increase in neutrophil and monocyte counts with thromboembolic events: The TRAVERSE trialThiago Gagliano-Jucá, Karol M Pencina, Yili V Shang, et al.
JAMA Cardiology|December 23, 2025
Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical TrialStephen J Nicholls, Donna H Ryan, John Deanfield, et al.
American Heart Journal|September 11, 2013
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trialA Michael Lincoff, Jean-Claude Tardif, Bruce Neal, et al.
Journal of the American College of Cardiology|June 21, 2005
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trialHitinder S Gurm, Ian J Sarembock, Dean J Kereiakes, et al.
The American Journal of Cardiology|December 28, 2014
Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarctionJosephine Warren, Roxana Mehran, Jennifer Yu, et al.
Circulation|April 30, 2003
Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injuryZhongmin Zhou, Kai Wang, Marc S Penn, et al.
Pageof 36